ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, today announced that the Miami Neuroscience Center at Larkin Community Hospital has fully transitioned its ...
Skoltech researchers and their colleagues from KTH Royal Institute of Technology, Sweden, have created an important building block for future 6G communication technology, which will make wireless data ...
WIth older-generation radiotherapy machines, each treatment session typically lasts about 10 minutes. With the new systems, ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancements in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr. Giulio ...
The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...
Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...
The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...
SHERBET, an individual patient data post hoc pooled analysis of 5 prospective trials, compared HDR-BT with SBRT in patients with intermediate-risk prostate cancer.
Lung cancer remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for a nuanced understanding of its diagnosis and treatment options, especially in special ...
Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical ...
MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results